Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: A useful surrogate

Journal of Urology

Volumn 191, Issue 4, 2014, Pages 898-906

  Lavery, Hugh J ^a   Stensland, Kristian D ^a   Niegisch, Guenter ^a,b   Albers, Peter ^a,b   Droller, Michael J ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

cystectomy; drug therapy; neoadjuvant therapy; risk assessment; urinary bladder neoplasms

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER PATIENT; CYSTECTOMY; DECISION TREE; DISEASE SPECIFIC SURVIVAL; HUMAN; MEDICAL RESEARCH; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MUSCLE INVASIVE BLADDER CANCER; MUSCLE INVASIVE UROTHELIAL BLADDER CANCER; OBSERVATION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSURETHRAL RESECTION; BLADDER CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; DIALYSIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; FATIGUE; HYDRONEPHROSIS; KIDNEY FAILURE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; NAUSEA AND VOMITING; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATHOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; RISK ASSESSMENT; RISK REDUCTION;

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE;

CYSTECTOMY; DRUG THERAPY; NEOADJUVANT THERAPY; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; DECISION TREES; HUMANS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSPECTIVE STUDIES; RISK ASSESSMENT; URINARY BLADDER NEOPLASMS;

EID: 84898427546     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.10.142     Document Type: Review

References (49)

1. A. Stenzl, N.C. Cowan, and M. De Santis et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2011 1009
2. P.E. Clark, N. Agarwal, and M.C. Biagioli et al. Bladder cancer J Natl Compr Canc Netw 11 2013 446
3. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA: Cancer J Clin 62 2012 10
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration Eur Urol 48 2005 202
5. H.B. Grossman, R.B. Natale, and C.M. Tangen et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859
6. A. Sherif, E. Rintala, and O. Mestad et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic Cystectomy Trial 2 Scand J Urol Nephrol 36 2002 419
7. E. Rintala, E. Hannisdahl, and S.D. Fosså et al. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I Scand J Urol Nephrol 27 1993 355
8. International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171
9. K.A. David, M.I. Milowsky, and J. Ritchey et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base J Urol 178 2007 451
10. M.P. Porter, M.C. Kerrigan, and B.M.K. Donato et al. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer Urol Oncol 29 2011 252
11. B.G. Volkmer, R. Kuefer, and G. Bartsch Jr. et al. Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival Cancer 104 2005 2384
12. G.S. Palapattu, S.F. Shariat, and P.I. Karakiewicz et al. Cancer specific outcomes in patients with pT0 disease following radical cystectomy J Urol 175 2006 1645
13. G. Gakis, C. Schwentner, and T. Todenhöfer et al. Current status of molecular markers for prognostication and outcome in invasive bladder cancer BJU Int 110 2012 233
14. H. Abol-Enein, D. Tilki, and A. Mosbah et al. Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study Eur Urol 60 2011 572
15. H.W. Herr, J.R. Faulkner, and H.B. Grossman et al. Surgical factors influence bladder cancer outcomes: a cooperative group report J Clin Oncol 22 2004 2781
16. R.E. Hautmann, R.C. de Petriconi, and C. Pfeiffer et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients Eur Urol 61 2012 1039
17. C.J. Weight, J.A. Garcia, and D.E. Hansel et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series Cancer 115 2009 792
18. L. Cheng, G.T. MacLennan, and A. Lopez-Beltran Histologic grading of urothelial carcinoma: a reappraisal Hum Pathol 43 2012 2097
19. O.N. Gofrit, K.C. Zorn, and G.D. Steinberg et al. The Will Rogers phenomenon in urological oncology J Urol 179 2008 28
20. C.T. Lee, R. Madii, and S. Daignault et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival J Urol 175 2006 1262
21. N.M. Fahmy, S. Mahmud, and A.G. Aprikian Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature Eur Urol 50 2006 1176
22. Bourgade V, Drouin SJ, Yates DR, et al. Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival. World J Urol 2013. Epub ahead of print.
23. R. Rosenblatt, A. Sherif, and E. Rintala et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 2012 122
24. D.F. Bajorin, P.M. Dodd, and M. Mazumdar et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 17 1999 3173
25. H. von der Maase, L. Sengelov, and J.T. Roberts et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer J Clin Oncol 23 2005 4602
26. S.B. Saxman, K.J. Propert, and L.H. Einhorn et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 15 1997 2564
27. A.S. Go, G.M. Chertow, and D. Fan et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296
28. R. Mayr, M. May, and T. Martini et al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder BJU Int 110 2012 E222
29. C.N. Sternberg, P. de Mulder, and J.H. Schornagel et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours Eur J Cancer 42 2006 50
30. A. Sherif, L. Holmberg, and E. Rintala et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies Eur Urol 45 2004 297
31. J.J. Meeks, J. Bellmunt, and B.H. Bochner et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 62 2012 523
32. M.D. Galsky, S.T. Tagawa, and S.F. Shariat Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit? J Urol 188 2012 358
33. C.-K. Tsao, B.A. Gartrell, and W.K. Oh et al. Emerging personalized approaches for the management of advanced urothelial carcinoma Expert Rev Anticancer Ther 12 2012 1537
34. M. Stöckle, W. Meyenburg, and S. Wellek et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience J Urol 153 1995 47
35. R. Sylvester, and C. Sternberg The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why Ann Oncol 11 2000 851
36. R.S. Svatek, S.F. Shariat, and G. Novara et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort BJU Int 107 2011 898
37. P.I. Karakiewicz, S.F. Shariat, and G.S. Palapattu et al. Precystectomy nomogram for prediction of advanced bladder cancer stage Eur Urol 50 2006 1254
38. M. Ploeg, L.A.L.M. Kiemeney, and G.A. Smits et al. Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy Urol Oncol 30 2012 247
39. M.L. Paik, M.J. Scolieri, and S.L. Brown et al. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy J Urol 163 2000 1693
40. S. Tritschler, C. Mosler, and D. Tilki et al. Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer Urology 79 2012 1317
41. A. Rajesh, H.K. Sokhi, and R. Fung et al. Bladder cancer: evaluation of staging accuracy using dynamic MRI Clin Radiol 66 2011 1140
42. D. Canter, T.J. Guzzo, and M.J. Resnick et al. Hydronephrosis is an independent predictor of poor clinical outcome in patients treated for muscle-invasive transitional cell carcinoma with radical cystectomy Urology 72 2008 379
43. Y. Lotan, A. Gupta, and S.F. Shariat et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy J Clin Oncol 23 2005 6533
44. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration: Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Eur Urol 48 2005 189
45. A. Dash, M.D. Galsky, and A.J. Vickers et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder Cancer 107 2006 506
46. S.H. Culp, R.J. Dickstein, and H.B. Grossman et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy J Urol 191 2014 40
47. G. Iyer, A.J. Hanrahan, and M.I. Milowsky et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 2012 221
48. I. Nordentoft, K. Birkenkamp-Demtroder, and M. Agerbæk et al. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer BMC Med Genomics 5 2012 40
49. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours Nature 490 2012 61